GALLANT 22 Tesaglitazar vs. Placebo
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes
Sponsor: AstraZeneca
Terminated
The development program has been terminated
Other terminated trials from AstraZeneca
Other Type 2 Diabetes trials with similar outcome
This PHASE3 trial investigates Type 2 Diabetes and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Angers, France , Athens, Greece , Aursmoen, Norway , Balatonfüred, Hungary , Belgrade, Serbia and Montenegro , Bergen, Norway , Bialystok, Poland , Borås, Sweden , Briollay, France and 91 more locations